NasdaqGM:EYPTPharmaceuticals
A Look at EyePoint Pharmaceuticals’s (EYPT) Valuation Following Steep Revenue Drop and Wider Quarterly Losses
EyePoint Pharmaceuticals (EYPT) just released third-quarter earnings, revealing that revenue fell sharply to $0.97 million from $10.5 million last year. Net loss nearly doubled during the same period.
See our latest analysis for EyePoint Pharmaceuticals.
Shares of EyePoint Pharmaceuticals have maintained solid momentum in 2024, with a year-to-date share price return of 44.2% and a 1-year total shareholder return of nearly 35%. While there was a dip in quarterly revenue, investors appear...